Cantor Fitzgerald Predicts CG Oncology FY2026 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of CG Oncology in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($3.58) for the year. Cantor Fitzgerald has a “Overweight” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.09). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.53 million.

CGON has been the subject of several other research reports. Morgan Stanley dropped their price target on CG Oncology from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Monday, May 19th. Scotiabank initiated coverage on CG Oncology in a research report on Wednesday, April 16th. They set a “sector perform” rating and a $23.00 price target for the company. JPMorgan Chase & Co. initiated coverage on CG Oncology in a research report on Friday, May 2nd. They set an “overweight” rating and a $41.00 price target for the company. Royal Bank of Canada raised their price target on CG Oncology from $66.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, CG Oncology presently has an average rating of “Buy” and a consensus target price of $58.22.

CG Oncology Stock Performance

CG Oncology stock opened at $26.18 on Wednesday. The stock has a fifty day moving average of $23.64 and a two-hundred day moving average of $26.99. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -17.34 and a beta of 0.86. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $40.47.

Institutional Investors Weigh In On CG Oncology

Institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in CG Oncology during the fourth quarter valued at about $41,000. CWM LLC grew its position in CG Oncology by 3,957.7% during the first quarter. CWM LLC now owns 2,110 shares of the company’s stock valued at $52,000 after acquiring an additional 2,058 shares during the period. GAMMA Investing LLC grew its position in CG Oncology by 1,051.0% during the first quarter. GAMMA Investing LLC now owns 2,302 shares of the company’s stock valued at $56,000 after acquiring an additional 2,102 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CG Oncology during the fourth quarter valued at about $68,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in CG Oncology during the fourth quarter valued at about $100,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.40% of the stock is owned by company insiders.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.